Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Antios Therapeutics
Antios thinks ATI-2173, which employs the Pharmasset liver-targeting chemistry used in HCV blockbuster Sovaldi, can help produce a functional cure in hepatitis B combination therapy.
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
- Chiral Chemistry
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Molecular Diversity